Merck KGaA stock (DE0006599905): Strong Q1 earnings beat and raised 2026 guidance

Merck KGaA reported robust Q1 2026 results on May 13, with revenues up 14% to EUR 1,544 million and raised full-year guidance, boosting investor interest in this science and technology leader.

Merck KGaA released its Q1 2026 earnings on May 13, 2026, surpassing expectations with non-GAAP EPS of EUR 2.11 versus a forecast of EUR 1.99 and revenues of EUR 1,544.2 million, a 14% increase from EUR 1,355 million a year earlier, according to GuruFocus as of 05/13/2026. The company also raised its 2026 guidance for group sales to EUR 20.4-21.4 billion and EBITDA pre to EUR 5.7-6.1 billion, signaling confidence amid strong segment performance.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck KGaA
• Sector/industry: Science and technology (Life Science, Healthcare, Electronics)
• Headquarters/country: Germany
• Core markets: Global, with strong US presence
• Key revenue drivers: Laboratory products, pharmaceuticals, electronics materials
• Home exchange/listing venue: Xetra (MRK.DE); OTC (MKGAF, MKKGY)
• Trading currency: EUR

Merck KGaA: core business model

Merck KGaA is a German multinational science and technology company operating in three key segments: Life Science, Electronics, and Healthcare. In Life Science, it supplies laboratory consumables, instruments, and services to biotech and pharma researchers worldwide. The Electronics division focuses on specialty chemicals for displays, semiconductors, and surface solutions, while Healthcare includes pharmaceuticals like Mavenclad for multiple sclerosis and Bavencio for oncology. This diversified model supports stable growth, with US investors noting its listings on OTC markets as MKGAF and MKKGY for easy access.

The company's strategy emphasizes innovation and sustainability, investing heavily in R&D to maintain leadership in high-tech materials and biopharma tools. For the quarter ended March 2026, organic sales grew moderately, as detailed in the earnings release on the company website as of 05/13/2026.

Main revenue and product drivers for Merck KGaA

Life Science remains the largest revenue contributor, driven by process solutions and consumables for bioprocessing, which saw record harvest volumes in Q1 2026. Electronics benefits from demand in OLED and semiconductor materials, while Healthcare grows through oncology and neurology drugs. Revenues reached EUR 1,544.2 million in Q1 2026, up 14% year-over-year per Zacks as of 05/13/2026, beating estimates by 3.89%.

Key drivers include strategic partnerships and M&A focus under new CEO Kai Beckmann, who assumed the role recently and prioritizes early-stage assets, according to Citeline as of 05/13/2026.

Industry trends and competitive position

Merck KGaA holds a strong position in the life sciences tools market, competing with Thermo Fisher and Danaher, bolstered by its integrated offerings from research to manufacturing. In electronics, it leads in liquid crystals and photoresists amid rising chip demand. For US investors, its exposure to biotech booms and semiconductor cycles aligns with key growth sectors.

Why Merck KGaA matters for US investors

Listed on US OTC markets, Merck KGaA provides US retail investors exposure to Europe's science tech leaders without direct ADR complexity. Its products fuel US biotech hubs and tech giants, tying performance to American innovation spending.

Conclusion

Merck KGaA's Q1 2026 results highlight resilient growth across segments, with raised guidance reflecting optimism under new leadership. While profitability shines, balance sheet considerations persist. US investors track its role in vital supply chains amid global tech shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.